Marvel Biosciences Corp.

Based in Calgary, Canada, Marvel Biosciences Corp. is a biotechnology firm dedicated to pre-clinical pharmaceutical development. The company focuses on identifying and advancing synthetic derivatives of existing medications, specifically those designed to inhibit the A2a adenosine receptor. Among its key assets are Nourianz (also known as Istradefylline or KW-6002) and MB-204, both of which function as adenosine A2A receptor antagonists. Its therapeutic pipeline addresses a range of conditions, including neurological disorders like Alzheimer's disease, depression, and anxiety, as well as non-neurological illnesses such as various cancers and non-alcoholic steatohepatitis (NASH).